What are GH secretagogue peptides?
GH secretagogue peptides are synthetic compounds that engage growth hormone-releasing hormone receptors (GHRH-R) or ghrelin receptors (GHS-R1a) on pituitary somatotrophs to drive growth hormone release. Two mechanistically distinct classes exist: GHRH analogs — CJC-1295, Sermorelin, and Tesamorelin — that activate GHRH receptors through cAMP-dependent pathways; and GH secretagogues — Ipamorelin — that activate ghrelin receptors via phospholipase C and intracellular calcium mobilization. Published research characterizes both receptor classes as G-protein coupled receptors (GPCRs) that stimulate growth hormone synthesis and secretion when activated (PMID: 15775957).
For performance research labs, these compounds serve as pharmacological tools for studying pituitary function, receptor pharmacology, and endocrine signaling in preclinical cell culture and animal models. The mechanistic distinction between GHRH-R and GHS-R1a agonists matters for experimental design — different receptor targets, different downstream signaling pathways, different compound selection criteria. These peptides are research tools, not therapeutic agents. All applications are for preclinical purposes only.
How do CJC-1295 variants differ?
CJC-1295 exists in two forms with distinct pharmacokinetic profiles that affect research application. CJC-1295 without DAC (Drug Affinity Complex) — also called Modified GRF (1-29) — is a 29-amino acid GHRH analog with sequence modifications at positions 2, 8, 15, 16, 23, 24, and 28 that improve metabolic stability compared to native GHRH. Published studies document that these substitutions extend half-life without compromising receptor binding affinity (PMID: 15775957). The non-DAC form provides a shorter duration of activity, making it the appropriate selection for research designs requiring acute receptor stimulation or pulse-dosing paradigms.
CJC-1295 with DAC includes the same peptide sequence plus a Drug Affinity Complex moiety enabling albumin binding, creating a circulating depot and extending terminal half-life substantially. Published pharmacokinetic studies characterize the DAC-modified form as releasing active peptide gradually from the albumin depot (PMID: 16452336). Both forms activate GHRH receptors through the same Gs-cAMP mechanism; the key experimental variable is duration of receptor engagement. Research applications should select the appropriate form based on the temporal requirements of the study design rather than defaulting to either variant.
What is the molecular structure of Ipamorelin?
Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, where Aib is aminoisobutyric acid and D-2-Nal is D-2-naphthylalanine. Molecular formula: C₃₈H₄₉N₉O₅ with molecular weight 711.9 g/mol (PMID: 10698741). D-amino acids at positions 2-Nal and Phe introduce proteolytic resistance. C-terminal amidation provides additional stability against exopeptidases. Published binding studies establish that Ipamorelin selectively activates the ghrelin receptor (GHS-R1a) with high affinity while showing minimal cross-reactivity at other pituitary hormone receptors including ACTH, prolactin, and cortisol pathways (PMID: 11916262). This receptor selectivity distinguishes Ipamorelin from non-selective GHRP compounds and is its primary research utility for performance labs studying ghrelin receptor biology.
The synthetic pentapeptide structure enables production via solid-phase synthesis with high purity. The non-standard amino acid content (Aib, D-2-Nal) requires careful analytical verification — mass spectrometry identity confirmation and HPLC purity are both required for reliable mechanistic research.
How does Sermorelin differ from native GHRH?
Sermorelin is a synthetic 29-amino acid peptide corresponding to the biologically active fragment of human GHRH — specifically GHRH(1-29) with acetate salt modification. The sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2. Published studies establish molecular weight of 3357.9 g/mol for the acetate salt (PMID: 8421207). This sequence represents the first 29 amino acids of native GHRH(1-44)OH, which retains full biological activity. Published structure-activity studies demonstrate that residues beyond position 29 in native GHRH contribute primarily to metabolic stability rather than receptor binding or activation. Sermorelin retains the native sequence without the additional modifications introduced in CJC-1295 variants.
Published receptor binding studies confirm Sermorelin activates GHRH receptors through the same Gs-protein coupled mechanism as native GHRH, stimulating adenylate cyclase and elevating cAMP in pituitary cell cultures. For performance research comparing native-sequence versus modified-sequence GHRH agonists, Sermorelin provides the unmodified reference compound against which modified analogs can be benchmarked.
What modifications does Tesamorelin contain?
Tesamorelin is a GHRH analog comprising GHRH(1-44) with a trans-3-hexenoyl group attached to the tyrosine at position 1. Published research details the 44-amino acid sequence with molecular weight 5135.9 g/mol (PMID: 19928588). The hexenoyl modification at the N-terminus provides lipophilicity that reduces renal clearance and proteolytic degradation compared to native GHRH — a different modification strategy than CJC-1295, which alters the peptide backbone sequence. Tesamorelin preserves the full GHRH(1-44) sequence while adding only the terminal moiety.
Published pharmacokinetic studies demonstrate extended half-life attributable to reduced renal clearance rather than altered receptor pharmacology. Binding studies confirm that Tesamorelin activates GHRH receptors through Gs-protein coupling with potency similar to native GHRH. For performance research requiring the full-length native GHRH sequence with improved stability — as opposed to truncated analogs — Tesamorelin is the appropriate research tool. The extended half-life enables study designs requiring sustained GHRH receptor activation over longer experimental windows.
How Do GH Secretagogue Peptides Compare?
| Feature | CJC-1295 NO DAC (Mod GRF 1-29) | CJC-1295 DAC | Ipamorelin | Sermorelin | Tesamorelin |
|---|---|---|---|---|---|
| Amino Acids | 29 | 29 | 5 | 29 | 44 |
| Molecular Weight | 3367.9 Da | 3647.4 Da | 711.9 Da | 3357.9 Da | 5135.9 Da |
| CAS Number | Mod GRF 1-29 | 863288-34-0 | 170851-70-4 | 86168-78-7 | 218949-48-5 |
| Receptor | GHRH-R | GHRH-R | GHS-R1a | GHRH-R | GHRH-R |
| Selectivity | GHRH selective | GHRH selective | GH selective | GHRH selective | GHRH selective |
| Key Modification | Sequence substitutions | DAC albumin binding | D-amino acids, Aib | Native sequence | Hexenoyl group |
| Mechanism | cAMP/PKA | cAMP/PKA | PLC/Ca2+ | cAMP/PKA | cAMP/PKA |
| Primary PMID | 15775957 | 16452336 | 10698741 | 8421207 | 19928588 |
FAQ
What concentration is used for GHRH receptor research?
Published in vitro studies typically use 1–100 nM for GHRH receptor activation in pituitary cell cultures. Higher concentrations (100–1000 nM) may be appropriate for receptor internalization or downstream pathway studies. Verify receptor expression in your cell model before finalizing concentration parameters.
Do GH secretagogues require GHRH for activity?
Published research demonstrates that GH secretagogues including Ipamorelin stimulate GH release through ghrelin receptor activation independently of GHRH. Synergistic effects between ghrelin receptor agonists and GHRH analogs are documented in published studies, reflecting the distinct but complementary receptor pathways.
What cell lines express GHRH receptors?
Published studies use primary pituitary cells, AtT-20 pituitary tumor cells, and HEK293 cells transfected with recombinant GHRH receptors. Verify receptor expression through binding assays or qPCR before experimental use (PMID: 15775957).
How stable are these peptides in culture media?
Peptide stability in culture media depends on sequence, protease content, and media composition. Published studies recommend fresh preparations or protease inhibitor inclusion. Modified CJC-1295 analogs show enhanced stability over native sequences due to sequence substitutions at protease-sensitive positions (PMID: 16452336).
Can these peptides be used in combination?
Published research demonstrates that GH secretagogues and GHRH analogs can be combined, with documented synergistic effects on GH release reflecting complementary receptor pathways. Design combination experiments with appropriate monoagonist controls and receptor antagonists to isolate individual compound contributions.
Research Use Only: All compounds sold by Prove It Performance are intended exclusively for laboratory research. Not for human or animal consumption. These products are not drugs, supplements, or food. Statements have not been evaluated by the FDA. Must be 21+ to purchase.